Overview
A market data
Price History
A price chart
Valuation & Profitability
- P/E (TTM)
- 29.37 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $4.57 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.23 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.7% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 19.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $108.35 – $160.27 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $41.5B · P/B 6.16 · P/S 5.74.
Company News
Morgan Stanley Maintains Overweight on Agilent Technologies, Raises Price Target to $175Benzinga · Aug 12, 2026, 3:37 PM
[Latest] Global gRNA Market Size/Share Worth USD 2950 Million by 2034 at a 19% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)Globenewswire Inc · Aug 6, 2026, 10:15 PM
AI Disruption Reshapes Bioinformatics: Record Investment and Breakthrough Tools Signal a New Era for Drug Discovery and Precision MedicineGlobenewswire Inc · Aug 6, 2026, 3:15 PM
Agilent Technologies shares are trading higher after the company announced it has received EU certification for PD-L1 IHC 22C3 pharmDx, in identifying epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.Benzinga · Jul 23, 2026, 2:34 PM
Agilent Technologies Receives EU Certification For Code SK006 As Companion Diagnostic To Aid In Identifying Patients With Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal CarcinomaBenzinga · Jul 23, 2026, 12:04 PM
Mass Spectrometry Market Size Worth USD 14.09 Billion by 2035 | SNS InsiderGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Cancer Biomarkers Market to Reach US$ 54.48 Billion by 2032 as Precision Oncology and Multi-Omics Adoption AccelerateGlobenewswire Inc · Jul 17, 2026, 11:15 AM
Oligonucleotide CDMO Market to Reach USD 9.87 Billion by 2031 as RNA-Targeted Drug Pipelines ExpandGlobenewswire Inc · Jul 15, 2026, 11:15 AM
Agilent Receives FDA Approval For The PD‑L1 LHC 28‑8 PharmDx Assay As Companion Diagnostic To Identify Patients With Carcinomas Who May Be Eligible For Treatment With OPDIVO or OPDIVO QVANTIGBenzinga · Jul 14, 2026, 12:08 PM
Agilent Expands Altura Portfolio With Intro Of Altura Size Exclusion Chromatography And Altura PLRP-S ColumnsBenzinga · Jul 8, 2026, 12:10 PM